drugset
drugset / Trial / NCT00424866

FGF-1 for Intramuscular Injection for the Treatment of Peripheral Arterial Disease

NCT00424866 ↗

Phase 1/2 Unknown 24 enrolled CardioVascular BioTherapeutics, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

FGF-1 for the treatment of patients with peripheral arterial disease with intermittent claudication.

Timeline

Start
2020-12
Primary completion
2021-12
Completion
2022-06

Drugs

EvaluationDrugModalityDoseRoute
Comparator FGF-1 Protein / enzyme biologic 3 ug/kg Intramuscular
Comparator FGF-1 Protein / enzyme biologic 10 ug/kg Intramuscular
Comparator FGF-1 Protein / enzyme biologic 30 ug/kg Intramuscular

Indications

intermittent vascular claudication peripheral arterial disease